The Intellectual Property
There is an increasing pipeline of targeted cancer therapies. However, there is limited precision in linking patients with therapy. The consequence of this limitation is a cost burden to society, a missed opportunity and a quality of life burden to patients.
FASTBASE SOLUTIONS has developed a high specificity, super-sensitive, quantitative biomarker platform employing A-FRET. This platform is designed to report on protein activation states and protein complex formation in situ, e.g. tumour biopsies.
FASTBASE SOLUTIONS investigates cell-cell interaction through determining cell-surface receptor and ligand synergy. Determining cell-cell contact provides insight into host communication with alternative cells including cancer cells. A specific example is an interaction between a patient’s immune system and tumour cells, providing a greater insight into host-tumour communication and the mechanisms involved in immune-mediated tumour destruction, immune-suppression and therapy resistance. FASTBASE SOLUTIONS, therefore, provides a platform for immune-therapy dosing regimen design.
FASTBASE SOLUTIONS offer a precision patient treatment through the use of more thorough and specific cancer prognosis.
FASTBASE SOLUTIONS have developed a high specificity, super-sensitive, quantitative biomarker platform employing A-FRET. This platform is designed to report on protein activation states and protein complex formation in situ e.g. tumour biopsies.
This quantitative imaging platform is an amplified signal imaging set-up for diagnostics and prognosis of cancer, enabling the evaluation of clinical efficiency of personalised cancer treatments.
It is an imaging system, composed of a proprietary adapted microscope powered by software based on a proprietary time-resolved A-FRET technique.